Market News

Juniper Pharmaceuticals, Inc. (JNP) Reaches $8.93 After 9.00% Up Move; Pioneer Tax Free Income Fund (PBF)’s Sentiment Is 0.86

Juniper Pharmaceuticals, Inc. (NASDAQ:JNP) Logo

The stock of Juniper Pharmaceuticals, Inc. (NASDAQ:JNP) is a huge mover today! The stock increased 2.59% or $0.225 during the last trading session, reaching $8.925. About 69,349 shares traded. Juniper Pharmaceuticals, Inc. (NASDAQ:JNP) has risen 115.66% since June 21, 2017 and is uptrending. It has outperformed by 103.09% the S&P500. Some Historical JNP News: 10/04/2018 – Juniper Research: Mixed Reality Apps to Exceed 9 billion by 2022, as Industry aims to Emulate Pokémon Go’s Success; 25/04/2018 – Juniper Pharmaceuticals Licenses Intravaginal Ring (IVR) Platform to Daré Bioscience; 17/04/2018 – Juniper Research: Loot Boxes & Skins Gambling to Generate a $50 Billion Industry by 2022; 06/03/2018 Juniper Research: Brain Machine Interface Hardware Revenues to Reach $19 Billion by 2027 Driven by Medical Applications; 25/04/2018 – DARÉ BIOSCIENCE, INC. ENTERS INTO EXCLUSIVE WORLDWIDE LICENSE AGREEMENT FOR JUNIPER PHARMACEUTICALS’ INTRAVAGINAL RING (IVR) TECHNOLOGY PLATFORM; 08/03/2018 – JUNIPER PHARMACEUTICALS INC – QTRLY BASIC SHR $0.11; 03/04/2018 – New Securematics and PureWRX Partnership Accelerates Adoption of Juniper Certified Pre-Owned Hardware; 09/04/2018 – Juniper Research – Online Physical Goods Sales to Account for 13% of $30 Trillion Retail Market by 2020; 25/04/2018 – JUNIPER PHARMACEUTICALS – ELIGIBLE TO RECEIVE UP TO $43.75 MLN IN MILESTONES FOR EACH IVR CANDIDATE, PLUS ROYALTIES ON FUTURE SALES; 09/03/2018 – Eucom: U.S. European commander visits troops participating in Juniper Cobra 2018The move comes after 8 months positive chart setup for the $99.08M company. It was reported on Jun, 21 by Barchart.com. We have $9.73 PT which if reached, will make NASDAQ:JNP worth $8.92M more.

Pioneer Tax Free Income Fund (PBF) investors sentiment decreased to 0.86 in 2018 Q1. It’s down -0.63, from 1.49 in 2017Q4. The ratio has worsened, as 119 hedge funds increased or started new stock positions, while 138 sold and decreased their equity positions in Pioneer Tax Free Income Fund. The hedge funds in our database now have: 104.33 million shares, down from 107.76 million shares in 2017Q4. Also, the number of hedge funds holding Pioneer Tax Free Income Fund in top ten stock positions decreased from 7 to 4 for a decrease of 3. Sold All: 40 Reduced: 98 Increased: 72 New Position: 47.

Among 5 analysts covering Juniper Pharmaceuticals Inc (NASDAQ:JNP), 2 have Buy rating, 0 Sell and 3 Hold. Therefore 40% are positive. Juniper Pharmaceuticals Inc has $33 highest and $6.75 lowest target. $17.25’s average target is 93.28% above currents $8.925 stock price. Juniper Pharmaceuticals Inc had 7 analyst reports since August 26, 2015 according to SRatingsIntel. The rating was downgraded by Bernstein on Monday, January 9 to “Market Perform”. The stock of Juniper Pharmaceuticals, Inc. (NASDAQ:JNP) earned “Buy” rating by Roth Capital on Tuesday, January 2. The stock has “Buy” rating by TheStreet on Wednesday, August 26. The firm has “Market Perform” rating by Northland Capital given on Thursday, August 18. The firm has “Outperform” rating given on Tuesday, January 26 by Northland Capital. The stock has “Neutral” rating by H.C. Wainwright on Friday, August 19.

Juniper Pharmaceuticals, Inc., a womenÂ’s health therapeutic company, focuses on developing therapeutics that address unmet medical needs in women's health. The company has market cap of $99.08 million. The firm develops its products using its drug delivery technologies, including bioadhesive delivery system, a polymer designed to adhere to epithelial surfaces or mucosa for sustained and controlled delivery of active drug product; and a novel intra-vaginal ring technology. It has a 178.5 P/E ratio. It markets CRINONE, a progesterone bioadhesive vaginal gel for progesterone supplementation or replacement as part of an assisted reproductive technology treatment for infertile women with progesterone deficiency.

Analysts await Juniper Pharmaceuticals, Inc. (NASDAQ:JNP) to report earnings on August, 2. They expect $0.04 earnings per share, up 233.33% or $0.07 from last year’s $-0.03 per share. JNP’s profit will be $444,038 for 55.78 P/E if the $0.04 EPS becomes a reality. After $0.06 actual earnings per share reported by Juniper Pharmaceuticals, Inc. for the previous quarter, Wall Street now forecasts -33.33% negative EPS growth.

Another recent and important PBF Energy Inc. (NYSE:PBF) news was published by Seekingalpha.com which published an article titled: “PBF Energy Pulls Back On ‘Collapsing’ Biofuels Mandate Deal” on June 06, 2018.

Analysts await PBF Energy Inc. (NYSE:PBF) to report earnings on August, 2. They expect $1.38 earnings per share, up 2,400.00% or $1.44 from last year’s $-0.06 per share. PBF’s profit will be $159.35M for 8.07 P/E if the $1.38 EPS becomes a reality. After $-0.29 actual earnings per share reported by PBF Energy Inc. for the previous quarter, Wall Street now forecasts -575.86% EPS growth.

Ratings analysis reveals 50% of PBF Energy’s analysts are positive. Out of 6 Wall Street analysts rating PBF Energy, 3 give it “Buy”, 0 “Sell” rating, while 3 recommend “Hold”. PBF was included in 6 notes of analysts from October 11, 2016. The company was downgraded on Tuesday, October 11 by Credit Suisse. The firm has “Outperform” rating by Wolfe Research given on Monday, November 14. The firm has “Neutral” rating given on Wednesday, April 5 by Goldman Sachs. On Tuesday, November 1 the stock rating was upgraded by Tudor Pickering to “Buy”. The stock of PBF Energy Inc. (NYSE:PBF) earned “Equal-Weight” rating by Morgan Stanley on Monday, February 27. Howard Weil downgraded PBF Energy Inc. (NYSE:PBF) on Wednesday, October 19 to “Sector Outperform” rating.

PBF Energy Inc., together with its subsidiaries, engages in the refining and supply of petroleum products. The company has market cap of $5.14 billion. The firm operates through two divisions, Refining and Logistics. It has a 10.56 P/E ratio. It produces gasoline, ultra-low-sulfur diesel, heating oil, diesel fuel, jet fuel, lubricants, petrochemicals, and asphalt, as well as unbranded transportation fuels, petrochemical feedstocks, blending components, and other petroleum products.

Towle & Co holds 3.54% of its portfolio in PBF Energy Inc. for 985,130 shares. Snow Capital Management Lp owns 2.02 million shares or 3.14% of their US portfolio. Moreover, Baupost Group Llc Ma has 2.59% invested in the company for 7.92 million shares. The New York-based New Amsterdam Partners Llc Ny has invested 2.5% in the stock. Spark Investment Management Llc, a New York-based fund reported 791,402 shares.

The stock decreased 3.09% or $1.42 during the last trading session, reaching $44.54. About 1.98 million shares traded. PBF Energy Inc. (PBF) has risen 118.47% since June 21, 2017 and is uptrending. It has outperformed by 105.90% the S&P500. Some Historical PBF News: 05/04/2018 – PBF’s Chalmette, Louisiana refinery begins alky unit restart; 23/04/2018 – DJ PBF Energy Inc Class A, Inst Holders, 1Q 2018 (PBF); 03/04/2018 – PBF CHALMETTE LOUISIANA REFINERY TO RESTART ALKY UNIT BY WEEKEND; 09/04/2018 – PBF Chalmette gasoline unit expected back by Thursday; 16/04/2018 – PBF Logistics Buys Cummin Terminal in Knoxville, Tenn; 12/04/2018 – PBF ENERGY CHALMETTE LOUISIANA REFINERY RESTARTING GASOLINE UNIT; 20/03/2018 – PBF Energy Closes Above 50-Day Moving Average: Technicals; 03/05/2018 – DELAWARE CITY REFINERY REFORMER WORK SET FOR NOVEMBER: PBF; 05/04/2018 – PBF Chalmette refinery plans begins alky unit restart; 03/05/2018 – PBF Energy 1Q Rev $5.8B

PBF Energy Inc. (NYSE:PBF) Institutional Positions Chart

Leave a Reply

Your email address will not be published. Required fields are marked *